1. Oxervate is a topical eyedrop that contains cenegermin. The drug treats neurotropic keratitis, a rare degenerative disease resulting in the loss of sensation in the cornea, which causes damage. It is the first drug approved in the U.S. to treat the disease.
2. Brainsway, an Israeli-based medical device manufacturer, received approval to market its Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder. The system is intended for use in patients with OCD that haven’t responded to traditional treatments.
3. Inveltys, a twice-daily ocular corticosteroid, is used to treat postoperative inflammation and pain after eye surgery.
4. Shire, a drugmaker based in Ireland, won approval for Takhzyro, a first-of-its-kind injection to prevent attacks of a rare swelling disorder, hereditary angioedema.
More articles on supply chain:
Medical device managers rely on physicians to screen out defects, study suggests
Amazon, other shippers ask Trump administration not to raise postal rates
Hospitals don’t save much on supply chain after they’re acquired, report says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
